AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.
While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as the first closed-loop therapy approach—allowing for self-adjusting neuromodulation in real time to help control the condition’s motor symptoms.
